酪氨酸激酶抑制剂诱导甲状腺功能减退的独特特征
本综述总结酪氨酸激酶抑制剂(TKI)干扰甲状腺激素稳态的机制与临床管理策略。TKI治疗常导致血清促甲状腺激素升高及T3/T4比值降低,涉及外周脱碘酶活性抑制;TKI诱导的甲减与生存改善相关,晚期恶性肿瘤中2型脱碘酶过表达可能介导抗肿瘤效应。
要点
- TKI治疗期间常见甲状腺激素异常,表现为TSH升高和T3/T4比值降低。
- TKI通过干扰外周组织脱碘酶活性影响甲状腺激素代谢。
- TKI诱导的甲减与改善的生存结局相关,需平衡耐受性与疗效。
核心结论
- TKI诱导的甲减具有独特特征,涉及外周甲状腺激素代谢干扰,尤其与脱碘酶活性抑制相关。
- TKI诱导的甲减与改善的生存结局相关,肿瘤组织2型脱碘酶过表达可能贡献抗肿瘤效应。
研究设计与样本
- 综述类文章,总结TKI诱导甲状腺激素稳态破坏的研究进展及临床管理策略。
主要发现
- TKI治疗期间常见血清TSH浓度升高和T3/T4比值降低,无论甲状腺完整还是已接受甲状腺激素治疗的甲减患者均可出现。
- TKI干扰健康组织中脱碘酶活性,可能显著贡献循环甲状腺激素浓度的变化。
- 晚期恶性肿瘤中2型脱碘酶过表达,抑制该酶可能参与TKI的抗肿瘤效应。
临床怎么用
- 在接受TKI治疗的患者中应监测甲状腺功能,关注TSH升高及T3/T4比值变化。
- 管理TKI诱导的甲减时需考虑其对TKI治疗耐受性的影响及与生存获益的关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tyrosine kinase inhibitors (TKIs) are anti-cancer agents that inhibit the activity of oncogenic protein kinases. Thyroid hormone abnormalities are common during treatment with TKIs, typically manifesting as increased serum thyroid stimulating hormone concentrations and reduced tri-iodothyronine (T3) to thyroxine (T4) ratio, both in patients with an intact thyroid gland and those with hypothyroidism receiving thyroid hormone treatment. Studies have highlighted the effect of TKIs on peripheral thyroid hormone metabolism, particularly through interference with the activity of deiodinases in healthy tissues. These enzymes are targets of TKIs, and their altered function might contribute considerably to the changes in circulating thyroid hormone concentrations. Although such alterations can affect the tolerability to TKI treatment, TKI-induced hypothyroidism has been associated with improved survival outcomes. Several advanced malignancies show overexpression of type 2 deiodinase, suggesting that inhibition of this enzyme in tumour tissue might contribute to the anti-tumour effects of TKIs. This Review summarises advances in the understanding of TKI-induced disruption of thyroid hormone homoeostasis, and discusses clinical strategies for managing hypothyroidism in this setting.
引用
- Porcelli T, De Stefano MA, Luongo C, et al. The unique signature of tyrosine kinase inhibitor-induced hypothyroidism. Lancet Diabetes Endocrinol. 2025. PMID: 40675173. doi:10.1016/S2213-8587(25)00193-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。